Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases

Liver International

Volumn 26, Issue 10, 2006, Pages 1217-1224

  Gonzalez Quintela, Arturo ^a,b   Mallo, Nieves ^a   Mella, Carmen ^a   Campos, Joaquín ^a   Perez, Luis Fernando ^a   Lopez Rodriguez, Raimundo ^a   Tome, Santiago ^a   Otero, Esteban ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Alcohol; Cytokeratin; Cytokeratin 18; Hepatitis; Hepatitis virus; Liver; Tissue polypeptide specific antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOKERATIN 18; LIVER ENZYME; RIBAVIRIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD SAMPLING; CHOLESTASIS; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FATTY LIVER; FEMALE; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PEPTIDES;

EID: 33750975876     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01380.x     Document Type: Article

References (24)

1. Omary MB, Ku NO, Toivola DM. Keratins: Guardians of the liver. Hepatology 2002; 5: 251-7.
2. Ku NO, Lim JK, Krams SM, et al. Keratins as susceptibility genes for end-stage liver disease. Gastroenterology 2005; 129: 885-93.
3. Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB. Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology 2004; 40: 459-66.
4. Barak V, Goike H, Panaretakis K, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37: 529-40.
5. Bonfrer JM, Groeneveld EM, Korse CM, Van Dalen A, Oomen LC, Ivanyi D. Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18. Tumor Biol 1994; 15: 210-22.
6. Rydlander L, Ziegler E, Bergman T, et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-14.
7. Einarsson R, Rydlander L. Tissue polypeptide specific antigen (TPS) detects a specific epitope structure on human cytokeratin. Anticancer Res 1997; 17: 3121-4.
8. Moraglio D, Pagano M, Galeazzi D, Arnelli A, Bertero L. Tissue polypeptide specific antigen (TPS) in liver disease. Clin Chim Acta 1994; 224: 209-14.
9. Kao CH, Gu CJ, Wang SJ. Tissue polypeptide specific antigen in hepatitis B carriers. Anticancer Res 1994; 14: 2817-8.
10. Cetin T, Oguz A, Algan P, Yildirim IS. The use of tissue polypeptide specific antigen as a marker in liver diseases. Turk J Gastroenterol 2003; 14: 177-80.
11. Gonzalez-Quintela A, Mella C, Pérez LF, Abdulkader I, Caparrini AM, Lojo S. Increased serum TPS (tissue polypeptide specific antigen) in alcoholics. A possible marker of alcoholic hepatitis. Alcohol Clin Exp Res 2000; 24: 1222-6.
12. Gonzalez-Quintela A, Mella C, Abdulkader I, et al. Serum levels of tissue polypeptide specific antigen are correlated with hepatocyte cytoqueratin expression in alcoholic liver disease. Alcohol Clin Exp Res 2004; 28: 1413-8.
13. Gonzalez-Quintela A, Garcia J, Campos J, et al. Serum cytokeratins in alcoholic liver disease: Contrasting levels of cytokeratin-18 and cytokeratin-19. Alcohol 2006; 38: 45-9.
14. Van Eiken P, Desmet VJ. Cytokeratins and the liver. Liver 1993; 13: 113-22.
15. Barros P, Gonzalez-Quintela A, Mella C, Perez LF. Increased urinary levels of tissue polypeptide specific antigen (TPS) in alcoholics. Anticancer Res 2006; 26: 1531-4.
16. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
17. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, Einarsson R, Van Dalen A. TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers 2004; 19: 115-9.
18. Collazos J, Genolla J, Ruibal A. A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepatic disorders. Scand J Clin Lab Invest 1993; 53: 633-7.
19. Kashiwabara K, Nakamura H, Kiguchi T, Matsuoka T. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases. Clin Chim Acta 1998; 273: 35-42.
20. Tu DG, Wang ST, Chang TT, Chiu NT, Yao WJ. The value of serum tissue polypeptide specific antigen in the diagnosis of hepatocellular carcinoma. Cancer 1999; 85: 1039-43.
21. Yao WJ, Chang TT, Wang ST, et al. Clinicopathologic correlation of serum tissue polypeptide specific antigen in hepatocellular carcinoma. Oncology 2001; 61: 64-70.
22. Sheard MA, Vojtesek B, Simickova M, Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 2002; 85: 670-7.
23. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751-6.
24. Ghavami S, Hashemi M, Kadkhoda K, Alavian SM, Bay GH, Los M. Apoptosis in liver diseases - detection and therapeutic applications. Med Sci Monit 2005; 11: RA337-45.